Esophagogastroduodenoscopy
Esophagogastroduodenoscopy has been studied in 12 papers since 2016: 1 trial and 10 observational studies in people, 1 review; 6 in the past year.
12 papers study it6 findingsUpdated
See all 11 papers on esophagogastroduodenoscopy
At a glance
The findings reach people, from one lab or study. 3 independent labs in 2 countries.
“Patients with Prior EGD had a 2-fold increased odds of early-stage gastric cancer compared with No Prior EGD (adjusted odds ratio: 2.05; 95% confidence interval [CI]: 1.82-2.31).”
None of its findings points the other way.
- 3 independent labs in 2 countries
- Funders: National Cancer Institute and 1 more
- 1 of 6 findings with company ties
- Human trial1
- Humans9
What did studies of esophagogastroduodenoscopy find?
1Studies of esophagogastroduodenoscopy measured one outcome, early-stage gastric cancer.
Early-stage gastric cancer
upin humans1
1 study
Early-stage gastric cancer
upin humans1
Esophagogastroduodenoscopy is linked with higher early-stage gastric cancer in humans (6-36 months before gastric cancer diagnosis) (adjusted odds ratio: 2.05; 95% CI: 1.82-2.31).
Humans6-36 months before gastric cancer diagnosisn = 15,871
What is esophagogastroduodenoscopy linked with?
4Studies link esophagogastroduodenoscopy with 4 measures, among them gastric adenocarcinoma, gastric precancerous conditions and gastric cancer mortality.
Gastric adenocarcinoma
upin humans1
1 study
Gastric adenocarcinoma
upin humans1
Esophagogastroduodenoscopy is associated with gastric adenocarcinoma in humans during colonoscopy within colorectal cancer screening (0.8% (3/377)).
Humansduring colonoscopy within colorectal cancer screeningstomachone-timen = 377
Gastric precancerous conditions
upin humans1+47%
1 study
Gastric precancerous conditions
upin humans1+47%
Esophagogastroduodenoscopy is associated with gastric precancerous conditions in humans during colonoscopy within colorectal cancer screening (46.9%).
Humansduring colonoscopy within colorectal cancer screeningstomachone-timen = 377
Gastric cancer mortality
downin humans1
1 study
Gastric cancer mortality
downin humans1
Esophagogastroduodenoscopy is linked with a lower risk of gastric cancer mortality in humans (6-36 months before gastric cancer diagnosis) (adjusted subdistribution hazard ratio: 0.64, 95% CI: 0.64-0.69).
Humans6-36 months before gastric cancer diagnosisn = 15,871
Mortality
downin humans1
1 study
Mortality
downin humans1
Esophagogastroduodenoscopy is linked with a lower risk of mortality in humans (6-36 months before gastric cancer diagnosis) (aHR 0.78, 95% CI 0.74-0.83).
Humans6-36 months before gastric cancer diagnosisn = 15,871
What acts on esophagogastroduodenoscopy?
1Studies name nonagenarians as acting on esophagogastroduodenoscopy.
Nonagenarians
downin humans1OR 0.86
1 study
Nonagenarians
downin humans1OR 0.86
Nonagenarians are linked with lower esophagogastroduodenoscopy in humans (NVUGIB) (30% vs. 48%, p<0.001; OR 0.86 (95% CI, 0.83-0.89)).
HumansNVUGIB